https://orcid.org/0000-0002-1129-4978
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard & Benjamin Besse. (2021) Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. Cancer Management and Research 13, pages 2805-2810.
Read now
Read now
Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park & Myung-Ju Ahn. (2020) Evaluating entrectinib as a treatment option for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 21:16, pages 1935-1942.
Read now
Read now
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea & Salvatore Siena. (2020) Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy 20:5, pages 333-341.
Read now
Read now
Articles from other publishers (7)
Akshansh Sharma, Devanshi Shambhwani, Sadanand Pandey, Jay Singh, Hauzel Lalhlenmawia, Murali Kumarasamy, Sachin Kumar Singh, Dinesh Kumar Chellappan, Gaurav Gupta, Parteek Prasher, Kamal Dua & Deepak Kumar. (2022) Advances in Lung Cancer Treatment Using Nanomedicines. ACS Omega 8:1, pages 10-41.
Crossref
Crossref
Tanuja Yadav, Velisha Mehta, Nilam Bhusare, Meena Chintamaneni & Y. C. Mayur. 2023. Drug Repurposing for Emerging Infectious Diseases and Cancer. Drug Repurposing for Emerging Infectious Diseases and Cancer
111
158
.
Amaiyya Agrawal & Sankha Bhattacharya. (2022) Cutting-edge Nanotechnological Approaches for Lung Cancer Therapy. Current Drug Research Reviews 14:3, pages 171-187.
Crossref
Crossref
Richard A. Ward, Stephen Fawell, Nicolas Floc’hVikki FlemingtonDarren McKerrecherPaul D. Smith. (2020) Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews 121:6, pages 3297-3351.
Crossref
Crossref
Lisa Mustachio & Jason Roszik. (2020) Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer. Pharmaceuticals 13:11, pages 374.
Crossref
Crossref
Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow & Giandomenico Roviello. (2020) Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers 12:11, pages 3293.
Crossref
Crossref
José Antonio Encinar & Javier A. Menendez. (2020) Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA. Viruses 12:5, pages 525.
Crossref
Crossref